Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy - Summary - MDSpire
Feature

Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy

New Eveo system is designed to raise CAR-T output, cut manufacturing costs, and ease cleanroom bottlenecks

  • April 7, 2026

  • 2 min

Share

Sartorius has unveiled the Eveo Cell Therapy Platform, a comprehensive manufacturing and quality control system aimed at revolutionizing autologous cell therapies, specifically CAR-T treatments. Addressing the high production costs and complexity of personalized therapies, the modular platform enhances efficiency by allowing multiple patient batches to be processed in parallel. Pilot testing with ElevateBio demonstrated significant improvements in output, allowing one operator to manage eight batches instead of two, potentially lowering CAR-T costs by 90%. Orders will begin in September 2026 with deliveries slated for 2027.

Original Source(s)

Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...